China channel feed – Endpoints News

China channel feed

#ASCO22: A small China biotech player makes its debut at ASCO with promising data on its GPRC5D multiple myeloma drug

4 years ago

#ASCO22: Legend, J&J say Carvykti holds up past the two-year mark as pair preps for potential second nod

4 years ago

Sequoia China leads $37M infusion into radiopharmaceuticals player setting up shop in China and Belgium

4 years ago

House Republicans attack China-only data in FDA submissions, seek new investigation into research inspections

4 years ago

As GSK-partnered Covid antibody racks up global sales, Vir axes WuXi deal and grabs back China rights

4 years ago

Fujifilm continues its biotech building spree with new facility in China

4 years ago

Chinese pharma giant Hengrui launches new company for globalization play — with a Merck KGaA vet at the helm

4 years ago

Under-the-radar Chinese biotech scores $47M upfront in secretive Merck deal around cancer drug

4 years ago

Chinese Alzheimer's drugmaker says lack of funding, Covid outbreak forced it to shutter international PhIII

4 years ago

Starna Therapeutics emerges with financing for mRNA vaccine and therapies

4 years ago

Scoop: Green Valley's seaweed-derived Alzheimer's drug, approved in China, is halted in PhIII study

4 years ago

SEC shines regulatory spotlight on I-Mab, Sinovac and others as more Chinese biotechs scramble to comply with new law

4 years ago

Frank Zhang is in the clear after Chinese authorities conclude investigation without charges, company says

4 years ago

FDA hits Hutchmed, Junshi drugs with CRLs — further clarifying its stance on China-only data

4 years ago

Novartis records another tislelizumab win en route to bringing BeiGene's PD-1 to FDA's doors

4 years ago

Vivo Capital pitches $60M to bring Arrowhead's RNAi meds to China via joint venture

4 years ago

Following BeiGene, Zai Lab changes auditors amidst SEC threat of delisting

4 years ago

Federal jury convicts Kansas chem professor on four counts in 'China Initiative' case

4 years ago

Spotting a gem from transpacific biotech, AstraZeneca pays $25M cash to pick up a preclinical bispecific antibody

4 years ago

After steering made-in-China CAR-T all the way from obscurity to approval, Frank Fan resigns from Legend

4 years ago

Harvard scientist Charles Lieber seeks acquittal in 'ill-conceived' China Initiative case

4 years ago

Most Chinese firms could keep their US listings under draft framework — report

4 years ago

Updated: SEC chair denies a deal to prevent Chinese company delisting is close — reports

4 years ago

As branded drug sales surge, analysts predict China market will remain 'very attractive'

4 years ago

First page Previous page 10 11 121314 15 16 Next page Last page